Skip to content

Allergan UK

About Allergan

Dedicated to Continuous Innovation for Your Well-Being

Allergan United Kingdom

Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people's lives.

Patient Group Support in 2008/2009/2010

In the UK, Allergan Ltd are proud to be able to partner the following patient organisations:

  • The International Glaucoma Association (IGA) - payment to cover the printing costs of a booklet for patients entitled "Dry Eye Syndrome - A Guide" (August 2008).
  • The Dystonia Society - Sponsorship of The Annual Conference of The Dystonia Society (November 2008).
  • The Stroke Association - payment to cover the reprinting costs of a factsheet for patients entitled "Physiotherapy Factsheet" (July 2009).
  • The European Dystonia Federation - educational grant to support projects and activities (2009/2010).
  • The Stroke Association - educational grant to support the "Moving On" campaign highlighting the importance of physiotherapy with stroke survivors (2009/2010).
  • The Royal National Institute for the Blind (RNIB) - educational grant to support the Wales Glaucoma Sibling Awareness Project (August 2010).
  • The Royal National Institute for the Blind (RNIB) - The provision of funding (£26,100) to support communication activities in support of retinal disease patients during October 2010-July 2011.
  • The Migraine Trust - The provision of funding (£20,000) to support communication activities to raise awareness of Migraine amongst Healthcare Practitioners and the General Public during July-December 2010.
  • The Royal National Institute for the Blind (RNIB) - The provision of funding (£25,000) to support communication activities to raise the profile of sight loss and treatment issues with Members of Parliament, Councilors and key decision makers during April–December 2011.